Emerging therapies for human papillomavirus infection

Expert Opinion on Emerging Drugs

Volumn 6, Issue 2, 2001, Pages 199-207

  Wilson, Francis X ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Aldara cream; Anogenital cancer; Antiviral; Cervical cancer; Genital warts; HPV; Imiquimod; Sexually transmitted disease; Vaccines

Indexed keywords

ANTIVIRUS AGENT; BLEOMYCIN; CAPSID PROTEIN; CATHARIDINE; CIDOFOVIR; COLCHICINE; CYTOTOXIC AGENT; FLUOROURACIL; GENE PRODUCT; IMIQUIMOD; IMMUNOMODULATING AGENT; NUCLEAR PROTEIN; PEN 203; PODOPHYLLOTOXIN; POLYPHENONE E; PRODUCT R; PROTEIN E2; PROTEIN E4; PROTEIN E5; PROTEIN E6; PROTEIN E7; PROTEIN L1; PROTEIN L2; RETICULOSE; THIOVIR; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN;

ANIMAL MODEL; CELL CULTURE; CLINICAL TRIAL; CONDYLOMA; CREAM; DRUG EFFICACY; DRUG TOLERABILITY; GENE EXPRESSION REGULATION; GENITAL TRACT CANCER; HUMAN; IMMUNOMODULATION; NONHUMAN; PATHOGENESIS; PRECANCER; REVIEW; SCAR FORMATION; SEXUALLY TRANSMITTED DISEASE; SKIN ULCER; UTERINE CERVIX CANCER; VIRUS ADSORPTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; WART VIRUS;

EID: 0035493725     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.2.199     Document Type: Review

References (96)

1. Analysis of the life cycle of human papillomavirus type 11 in a cell culture model
2. Epidemiology of genital human papillomavirus infection
3. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
4. Papillomaviruses causing cancer: Evasion from host-cell control in early events in Carcinogenesis
5. Therapeutic approaches to genital warts
6. Management of genital infection caused by human papillomavirus
7. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts
8. Interferon treatment of anogenital human papillomavirus-related diseases
9. Imiquimod applied topically: A novel immune response modifier and new class of drug
10. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R842 in human blood cells in vitro
11. A randomised, controlled, molecular study of condyloma acuminata clearance during treatment with imiquimod
12. Self-administered topical 5% imiquimod cream for external anogenital warts
13. New treatments for genital warts less than ideal: Abstract and commentary
14. In vitro and animal models for antiviral therapy in papillomavirus infections
15. Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse
16. Synthesis antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cystosine
17. Identification of the alpha-6 integrin as a candidate receptor for papillomaviruses
18. α6 integrin is the main receptor of human papillomavirus type 16 VLP
19. α6 integrin is not the obligatory cell-receptor for bovine papillomavirus type 4
20. Human papillomavirus infection requires cell surface heparan sulfate
21. Human papillomavirus type 16 minor capsid protein L2 N-terminal region containing a common neutralisation epitope binds to the cell surface and enters the cytoplasm
22. Replication-associated activities of purified human papillomavirus type 11 E1 helicase
23. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex
24. Characterisation of the helicase and ATPase activity of human papillomavirus type 6b E1 protein
25. DNA helicases
26. A fluorescence-based assay for monitoring helicase activity
27. Characterisation of Bacillus stearothermophilus PcrA
28. Comparison between the structures of HCV and rep helicases reveal structural similarities between SF1 and SF2 superfamilies of helicases
29. Crystal structure of RNA helicase from genotype 1b hepatitis C virus - A feasible mechanism of unwinding duplex RNA
30. DNA replication at high resolution
31. DNA helicases: 'Inching forward'
32. A general model for nucleic acid helicases and their 'coupling' within macromolecular machines
33. The DnaB.DnaC complex: A structure based on dimers assembled around an occluded channel
34. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21 CIP-dependent pathways
35. The papillomavirus E2 regulatory proteins
36. Mapping and characterisation of the interaction domains of human papillomavirus type 16 E1 and E2 proteins
37. Structure of the intact transactivation domain of the human papillomavirus E2 protein
38. Crystal structure of the human papillomavirus type 18 E2 activation domain
39. E2 polypeptides encoded by bovine papillomavirus type 1 form dimers through the common carboxy terminal domain; Transactivation is mediated by the conserved aminoterminal domain
40. Crystal structure at 1.7A of the bovine papillomavirus-1 E2 DNA-binding domain bound to its DNA target
41. Solution structure of the DNA binding domain of a human papillomavirus E2 protein: Evidence for flexible DNA-binding regions
42. Papillomavirus E2 induces p53-independent apoptosis in HeLa cells
43. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway
44. Inhibition of the bovine papillomavirus E2 protein activity by peptide nucleic acid
45. A fifteen amino acid peptide inhibits human papillomavirus E1-E2 interaction and human papillomavirus DNA replication in vitro
46. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein
47. Identification of the human papillomavirus-1a E4 gene products
48. Sequence divergence yet conserved physical characteristics among the E4 proteins of cutaneous human papillomaviruses
49. Specific interactions between HPV16 E1∧E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network
50. Immunoelectron microscopical localisation of the human papillomavirus type 16 L1 and E4 proteins in cervical keratinocytes cultured in vitro
51. Mutational analysis of human papillomavirus E4 proteins: Identification of structural features important in the formation of cytoplasmic E4/cytokeratin networks in epithelial cells
52. Analysis of HPV E4 complexes and their associations with keratins in vivo
53. DNA sequence of the HPV-16 E5 ORF and the structural conservation of its encoded protein
54. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein
55. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes
56. The HPV16 E5 oncogene inhibits endocytic trafficking
57. +-ATPase function and stability in Saccharomyces cerevisiae
58. +-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation
59. Targeted disruption of the epidermal growth factor receptor inhibits development of papillomas and carcinomas from human papillomavirus-immortalised keratinocytes
60. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa) an inhibitor of EGFR tyrosine kinase
61. In vivo ubiquitination and proteasome-mediated degradation of p53
62. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: Based on E6-E6AP binding
63. Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomaviruses of cutaneous origin
64. The papillomavirus E6 proteins
65. Gps2, a protein partner for human papillomavirus E6 proteins
66. Telomerase activation by the E6 gene product of human papillomavirus type 16
67. Telomerase activation by human papillomavirus type 16 E6 protein: Induction of human telomerase reverse transcriptase expression through Myc GC-rich Sp1 binding sites
68. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein
69. HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognises four-way junctions
70. Potential drugs against cervical cancer: Zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein
71. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulphides
72. The human papillomavirus-E7 protein as a transforming and transactivating factor
73. The E7 oncoprotein of human papillomavirus type 16 interacts with F-actin in vitro and in vivo
74. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-α
75. Inactivation of interferon regulatory factor-1 tumour suppressor protein by HPV E7 oncoprotein: Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis
76. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1
77. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21 Cip1-mediated inhibition of cdk2
78. Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry
79. Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes
80. Structural and functional characterisation of the HPV16 E7 protein expressed in bacteria
81. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7
82. Interaction of papillomaviruses with the cell surface
83. Efficient self-assembly of human papillomavirus type-16 L1 and L2 into virus-like particles
84. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro
85. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2mRNA of papillomavirus: Potential treatment for genital warts
86. Non-specific antiviral activity of antisense molecules targeted at the E1 region of human papillomavirus
87. Vaccines for human-papillomavirus-associated anogenital disease and cervical cancer: Practical and theoretical approaches
88. Overview of vaccinology with special reference to papillomavirus vaccines
89. A dose-ranging study of the safety and immunogenicity profiles of an HPV 11 L1 VP candidate vaccine in young healthy women